Wire · opportunities
FDA Approves First CELMoD Drug for Multiple Myeloma
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 13 August 2026 · Fusion42 review
The FDA granted accelerated approval to iberdomide (Zenbexus), the first cereblon E3 ligase modulation (CELMoD) therapy, for relapsed or refractory multiple myeloma in combination with daratumumab, hyaluronidase, and dexamethasone, showing improved minimal residual disease-negative complete response rates.
This Wire brief sits within Fusion42's coverage of Biotech, and 12 sources have reported it between 13 Aug 2026 and 17 Aug 2026.
◆ ◆ The Wire takeaway
You can now access a new drug class for relapsed multiple myeloma that improves deep remission rates but must navigate complex safety rules including embryo-fetal toxicity and thrombosis risks.
◆ Coverage
12 sources · first reported 13 Aug 2026 · latest 17 Aug 2026
◆ Topics